(504A) Stock Price

Innovacell is a pharmaceutical development company that develops and commercializes cell therapy products using human skeletal muscle cells. The company has developed a treatment method that aims to restore muscle function by injecting myoblasts harvested from a patient's own muscle tissue into damaged muscle tissue. Currently, the company holds three product pipelines specialized in the incontinence field (urinary and fecal incontinence). The company's core technology is the ability to supply high-quality cell products in facilities that comply with good manufacturing practice standards.

The company's revenue structure consists of diverse revenue sources according to the product development stage. Following regulatory approval of its lead product, the company expects one-time payments and milestone revenues from co-promotion agreements with pharmaceutical companies, as well as product sales revenues to pharmaceutical wholesalers. For other development candidates, the company also anticipates future revenues from licensing-out contracts, development collaboration fees, and royalty income. Additionally, manufacturing contract revenues from its European subsidiary are planned to form part of revenues.

The company's business consists of a single segment: "Cell Therapy and Regenerative Medicine Research and Development." The development pipeline comprises three products: ICEF15 for urgent fecal incontinence (currently in Phase 3 international joint clinical trials), ICEF16 for passive fecal incontinence (Phase 1/2 trial preparation underway), and ICES13 for stress urinary incontinence (Phase 2 late-stage trials completed in Europe). These products are characterized by lower invasiveness compared to existing surgical treatments and aim for fundamental restoration of muscle function, providing first-mover advantage as no approved competing products currently exist.

Innovacell aims to address unmet medical needs through the development and commercialization of innovative cell therapy products using human cells. The company employs a distinctive "Cell Therapy and Regenerative Medicine Global Aggregation Model," which is not dependent on any specific technology. Instead, it identifies promising cell therapy candidates from around the world and combines them with optimal business infrastructure for commercialization. Currently, the company holds three autologous cell therapy pipelines focused on the incontinence field. Its primary objectives are to obtain regulatory approval for its flagship product ICEF15 in Japan and Europe, and to achieve early revenue generation from operations.

The company's priority investment area is completing Phase 3 international clinical trials for ICEF15, targeting urgency fecal incontinence, and establishing a commercialization infrastructure. Significant market opportunities exist, with approximately 120,000 patients in Japan, 430,000 in Europe, and 320,000 in the United States. The company has established a first-mover advantage with no existing competing products. In November 2024, the company entered into a basic partnership agreement with Alfresa, granting exclusive wholesale distribution rights in Japan, steadily advancing its sales and distribution system. In Western markets, negotiations are underway with comprehensive commercialization service providers for definitive agreements.

For new market development, the company will begin FDA consultations in July 2025 regarding the Phase 3 international clinical trial of ICEF15 in the United States, the world's largest market. In parallel, the company is preparing for Phase 1/2 clinical trials of ICEF16 (for fecal incontinence from leakage) beginning in 2026 and pivotal trial preparations for ICES13 (for stress urinary incontinence). The company anticipates cross-selling opportunities through synergies with ICEF15. Through this product portfolio, the company aims to provide comprehensive solutions in the incontinence field.

Regarding technological innovation, the company actively expands its research and development pipeline, including verification of potential applications for improved swallowing function through joint research with Saga University. Swallowing disorders in aging societies represent a global challenge and are expected to become a new therapeutic area leveraging the company's myoblast cell technology. The company also actively participates in cell therapy-related events in Japan, the United States, and Europe to gather the latest information and conducts negotiations on multiple research and development candidates to support future revenue expansion and risk diversification.